Seminars in Cancer Biology

Article	Citations
Ferroptosis is a type of autophagy-dependent cell death	524
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer	288
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	249
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges	217
The role of SOX family members in solid tumours and metastasis	206
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy	191
Emerging roles of ECM remodeling processes in cancer	174
SOX2 in development and cancer biology	172
Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins	172
Radiomics in breast cancer classification and prediction	166
Targeting p53 for the treatment of cancer	162
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression	154
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond	153
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics	145
Translational genomics and recent advances in oral squamous cell carcinoma	143
Risk of colorectal cancer in inflammatory bowel diseases	140
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	139
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review	130
Immune checkpoints in the tumor microenvironment	130
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	129
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives	124
An update on vitamin D signaling and cancer	122
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects	119
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	118
lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions	117

Revisiting the hallmarks of cancer: The role of hyaluronan	117
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers	116
Machine and deep learning approaches for cancer drug repurposing	114
RAF-MEK-ERK pathway in cancer evolution and treatment	112
Regulation of autophagy by canonical and non-canonical ER stress responses	111
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies	109
Pathology of triple negative breast cancer	108
SOX4: The unappreciated oncogene	105
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	103
Dietary fat, bile acid metabolism and colorectal cancer	101
The complexity of p53-mediated metabolic regulation in tumor suppression	98
An updated overview on metal nanoparticles toxicity	96
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics	95
Regulation and function of SOX9 during cartilage development and regeneration	94
The mutational landscape of mucosal melanoma	94
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer	93
PROTACs: A novel strategy for cancer therapy	90
Precision medicine in non-small cell lung cancer: Current applications and future directions	89
Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges	88
Artificial intelligence aids in development of nanomedicines for cancer management	88
Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement	87
Thyroid autoimmune disorders and cancer	87
Combining epigenetic and immune therapy to overcome cancer resistance	85
DNMT1: A key drug target in triple-negative breast cancer	85
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	84
Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement	84
Antibody therapeutics and immunoregulation in cancer and autoimmune disease	83
RNA methylations in human cancers	83
Translational genomics of nasopharyngeal cancer	82
The Skp2 Pathway: A Critical Target for Cancer Therapy	81
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer	80
Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds	79
Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator	78
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies	78
Tumor intrinsic and extrinsic immune functions of CD155	78
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature	77
Neutrophil extracellular traps in cancer	75
The impact of VEGF on cancer metastasis and systemic disease	75
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics	74
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications	74
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches	74
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	73
Recent insight into the role of FBXW7 as a tumor suppressor	72
Drug repurposing for breast cancer therapy: Old weapon for new battle	72
Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review	70
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis	69
Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis	68
The oral microbiota and its role in carcinogenesis	68
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy	68
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy	67

NEDD4 E3 ligase: Functions and mechanism in human cancer	66
Dissenting degradation: Deubiquitinases in cell cycle and cancer	66
Extracellular vesicles in cancer nanomedicine	65
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives	65
Colorectal cancer occurrence and treatment based on changes in intestinal flora	65
Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives	63
Predictive biomarkers for response to immune checkpoint inhibition	63
EGFR signaling pathway as therapeutic target in human cancers	62
PD-L1 status in breast cancer: Current view and perspectives	62
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	62
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	62
SOX4: Epigenetic regulation and role in tumorigenesis	62
At a glance: A history of autophagy and cancer	62
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy	61
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	60
Functionalized mesoporous silica nanoparticles in anticancer therapeutics	60
Circular RNAs in cancer: Limitations in functional studies and diagnostic potential	60
Epigenetics in hepatocellular carcinoma	59
TGF-β in developmental and fibrogenic EMTs	59
The functions and regulation of Smurfs in cancers	58
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets	57
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis	57
Hedgehog signaling mechanism and role in cancer	56
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy	56
Determinants of response and resistance to CAR T cell therapy	55
The potential of liquid biopsy in the management of cancer patients	55
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	55
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress	55
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer	54
Role of heparanase in tumor progression: Molecular aspects and therapeutic options	54
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis	54
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy	54
Role of cell surface proteoglycans in cancer immunotherapy	53
Solid stress, competition for space and cancer: The opposing roles of mechanical cell competition in tumour initiation and growth	53
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer	52
Engineered nanoparticles for imaging and drug delivery in colorectal cancer	52
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer	52
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases	52
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	51
Cellular heterogeneity and plasticity in liver cancer	51
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	51
Circular RNAs as biomarkers and therapeutic targets in cancer	51
Chemokines in colon cancer progression	51
The intricacies of NRF2 regulation in cancer	50
Role of iron in cancer	50
RBR E3 ubiquitin ligases in tumorigenesis	50
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis	50
Repurposing of drugs as STAT3 inhibitors for cancer therapy	49
Proteomic research in sarcomas – current status and future opportunities	49
Systems biology based drug repositioning for development of cancer therapy	49
miRNA dysregulation is an emerging modulator of genomic instability	48
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	48
Implications of nanotechnology for the treatment of cancer: Recent advances	48
Nano-immunotherapy: Overcoming tumour immune evasion	47
The role of senescence in cancer development	47
Effects of statins on brain tumors: a review	47
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19	47
Intracellular hyaluronan: Importance for cellular functions	47
Nanoparticle mediated cancer immunotherapy	47
Glyco-nanoparticles: New drug delivery systems in cancer therapy	47
Repurposing quinacrine for treatment-refractory cancer	47
AMPK signaling and its targeting in cancer progression and treatment	46
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance	46
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology	46
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review	45
Regulatory roles for SOX11 in development, stem cells and cancer	43
Epithelial defense against cancer (EDAC)	43
Tumor glycolysis, an essential sweet tooth of tumor cells	43
Probiotics in microbiome ecological balance providing a therapeutic window against cancer	43
Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme	43
Biological functions of therapy-induced senescence in cancer	43
How far have we explored fungi to fight cancer?	43
Emerging roles of long non-coding RNAs in breast cancer biology and management	42
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	42
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research	42
Anticancer activity of lactic acid bacteria	42
Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development	42
Mechanisms of cancer metastasis	42
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic	42
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives	41

Noncoding RNAs as potential mediators of resistance to cancer immunotherapy	41
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance	41
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation	41
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	40
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	40
RNA-binding proteins and cancer metastasis	40
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	40
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib	40
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment	40
Turning liabilities into opportunities: Off-target based drug repurposing in cancer	40
Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma	39
Small cell lung cancer transformation: From pathogenesis to treatment	38
Genome chaos: Creating new genomic information essential for cancer macroevolution	38
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	38
Epigenetic modifications of autophagy in cancer and cancer therapeutics	38
Repurposing drugs in oncology: From candidate selection to clinical adoption	38
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine	38
Uveal melanoma pathobiology: Metastasis to the liver	37
The evolutionary legacy of immune checkpoint inhibitors	37
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	37
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	37
Interference between copper transport systems and platinum drugs	37
The pleiotropic role of proteoglycans in extracellular vesicle mediated communication in the tumor microenvironment	37
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy	37
Polyploidy formation in cancer cells: How a Trojan horse is born	37
The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance	37
New Advances in Molecular Breast Cancer Pathology	37
SOX17 in cellular reprogramming and cancer	36
Cyclin D degradation by E3 ligases in cancer progression and treatment	36
Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges	36
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?	36
Cancer stem cells in TNBC	36
ITCH as a potential therapeutic target in human cancers	36
Vimentin and cytokeratin: Good alone, bad together	35
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	35
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer	35
MicroRNA and ER stress in cancer	35
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy	35
Roles of microbiota in response to cancer immunotherapy	35
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies	35
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	35
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective	35
Cullin-RING Ligase 5: Functional characterization and its role in human cancers	35
Paradoxes of cancer: Survival at the brink	34
Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer	34
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy	34
Gold nanoparticles and cancer: Detection, diagnosis and therapy	34
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer	34
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment	34
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	34
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	34
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	33
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment	33
Dietary isothiocyanates inhibit cancer progression by modulation of epigenome	33
Autophagy in cancer: Recent advances and future directions	33
Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches	33
Clinical utility of whole-genome sequencing in precision oncology	33
Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: Micromanaging by not so small non-coding RNAs	32
Novel therapeutic strategies for spinal osteosarcomas	32
Vaginal microbiome and cervical cancer	32
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era	32
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy	32
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors	32
Significance of human microbiome in breast cancer: Tale of an invisible and an invincible	32
The clinical value of detecting microcalcifications on a mammogram	32
The unique immune microenvironment of liver metastases: Challenges and opportunities	32
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	32
Emerging applications of bacteria as antitumor agents	32
Carcinogenic microbiota and its role in colorectal cancer development	32
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	32
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment	32
Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention	32
Proteoglycan signaling in tumor angiogenesis and endothelial cell autophagy	32